» Articles » PMID: 12504883

Transient Ischemia of the Retina Results in Altered Retrograde Axoplasmic Transport: Neuroprotection with Brimonidine

Overview
Journal Exp Neurol
Specialty Neurology
Date 2002 Dec 31
PMID 12504883
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

In adult rats we have induced retinal ischemia and investigated retrograde axonal transport in ganglion cells. The animals received in their left eyes, 1 h prior to ischemia, two 5-microl drops of saline or 0.5% brimonidine (BMD). Retinal ischemia was induced by transient ligature of the left ophthalmic vessels for 90 min. One hour or 1 week after ischemia, Fluorogold (FG) was applied to both superior colliculi, the animals were processed 1 week after FG application, and FG-labeled retinal ganglion cell (RGC) densities were estimated in the right control and left experimental retinas. In the left retinas of the saline-pretreated animals, RGC densities diminished to 39 or 30% of the densities found in their right control retinas, 7 or 14 days after ischemia, respectively. Because in a previous similar study in which FG was applied 7 days before ischemia, the percentages of FG-labeled RGCs were 54 and 48%, 7 and 14 days after ischemia, respectively, this suggests that retrograde axonal transport was impaired in some surviving RGCs. This was confirmed in an additional group of rats in which 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate was applied to both SCi 3 weeks before ischemia, and FG was applied to the intraorbitally cut optic nerve 9 days after ischemia and 5 days before euthanization. In the left retinas of the BMD-pretreated animals, RGC densities amounted to 90% of the RGC population 7 or 14 days after ischemia and were comparable to those obtained in their contralateral nonischemic retinas. Retinal ischemia causes RGC loss and induces alterations of retrograde axonal transport in a proportion of surviving RGCs. BMD rescues RGCs from ischemia-induced cell death and preserves retrograde axonal transport in surviving RGCs.

Citing Articles

Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future.

Amankwa C, Kodati B, Donkor N, Acharya S Biomedicines. 2023; 11(11).

PMID: 38001960 PMC: 10669210. DOI: 10.3390/biomedicines11112959.


Pan-retinal ganglion cell markers in mice, rats, and rhesus macaques.

Nadal-Nicolas F, Galindo-Romero C, Lucas-Ruiz F, Marsh-Amstrong N, Li W, Vidal-Sanz M Zool Res. 2023; 44(1):226-248.

PMID: 36594396 PMC: 9841181. DOI: 10.24272/j.issn.2095-8137.2022.308.


7,8-Dihydroxiflavone Maintains Retinal Functionality and Protects Various Types of RGCs in Adult Rats with Optic Nerve Transection.

Gallego-Ortega A, Vidal-Villegas B, Norte-Munoz M, Salinas-Navarro M, Aviles-Trigueros M, Villegas-Perez M Int J Mol Sci. 2021; 22(21).

PMID: 34769247 PMC: 8584116. DOI: 10.3390/ijms222111815.


Topical Brimonidine or Intravitreal BDNF, CNTF, or bFGF Protect Cones Against Phototoxicity.

Valiente-Soriano F, Ortin-Martinez A, Di Pierdomenico J, Garcia-Ayuso D, Gallego-Ortega A, Miralles de Imperial-Ollero J Transl Vis Sci Technol. 2020; 8(6):36.

PMID: 31890348 PMC: 6919195. DOI: 10.1167/tvst.8.6.36.


Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.

Yokoyama Y, Kawasaki R, Takahashi H, Maekawa S, Tsuda S, Omodaka K J Glaucoma. 2019; 28(7):575-583.

PMID: 31188229 PMC: 7055936. DOI: 10.1097/IJG.0000000000001285.